DK2358698T3 - Tetrasubstitueret pyridazin som hedgehog-pathway antagonister - Google Patents

Tetrasubstitueret pyridazin som hedgehog-pathway antagonister

Info

Publication number
DK2358698T3
DK2358698T3 DK09752059.7T DK09752059T DK2358698T3 DK 2358698 T3 DK2358698 T3 DK 2358698T3 DK 09752059 T DK09752059 T DK 09752059T DK 2358698 T3 DK2358698 T3 DK 2358698T3
Authority
DK
Denmark
Prior art keywords
hedgehog
tetra
pathway antagonists
substituted pyridazine
pyridazine
Prior art date
Application number
DK09752059.7T
Other languages
Danish (da)
English (en)
Inventor
Jolie Anne Bastian
Julia Marie Clay
Jeffrey Daniel Cohen
Philip Arthur Hipskind
Karen Lynn Lobb
Daniel Jon Sall
Takako Wilson
Michelle Lee Thompson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2358698T3 publication Critical patent/DK2358698T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK09752059.7T 2008-11-17 2009-11-05 Tetrasubstitueret pyridazin som hedgehog-pathway antagonister DK2358698T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11533208P 2008-11-17 2008-11-17
PCT/US2009/063370 WO2010056588A1 (en) 2008-11-17 2009-11-05 Tetrasubstituted pyridazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
DK2358698T3 true DK2358698T3 (da) 2012-10-08

Family

ID=41722877

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09752059.7T DK2358698T3 (da) 2008-11-17 2009-11-05 Tetrasubstitueret pyridazin som hedgehog-pathway antagonister

Country Status (18)

Country Link
US (1) US8507490B2 (enExample)
EP (1) EP2358698B1 (enExample)
JP (1) JP5518887B2 (enExample)
KR (1) KR101342184B1 (enExample)
CN (1) CN102216285B (enExample)
AU (1) AU2009314349B2 (enExample)
BR (1) BRPI0921782A2 (enExample)
CA (1) CA2743483C (enExample)
CY (1) CY1113377T1 (enExample)
DK (1) DK2358698T3 (enExample)
EA (1) EA017386B1 (enExample)
ES (1) ES2392759T3 (enExample)
HR (1) HRP20120762T1 (enExample)
MX (1) MX2011005177A (enExample)
PL (1) PL2358698T3 (enExample)
PT (1) PT2358698E (enExample)
SI (1) SI2358698T1 (enExample)
WO (1) WO2010056588A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714872A2 (pt) * 2006-07-17 2013-03-19 Syngenta Participations Ag derivados de piridazina
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
CN110208424A (zh) * 2019-06-28 2019-09-06 江苏恒生检测有限公司 一种农药氟啶虫酰胺中含有杂质的分析方法
WO2021071981A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US20250333397A1 (en) * 2021-08-30 2025-10-30 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
US8507490B2 (en) 2013-08-13
AU2009314349A1 (en) 2010-05-20
HRP20120762T1 (hr) 2012-10-31
CA2743483A1 (en) 2010-05-20
CN102216285B (zh) 2014-08-13
MX2011005177A (es) 2011-05-30
KR101342184B1 (ko) 2013-12-19
AU2009314349B2 (en) 2013-04-18
JP5518887B2 (ja) 2014-06-11
PL2358698T3 (pl) 2013-01-31
KR20110070920A (ko) 2011-06-24
PT2358698E (pt) 2012-10-24
EP2358698B1 (en) 2012-09-05
ES2392759T3 (es) 2012-12-13
US20110263602A1 (en) 2011-10-27
CY1113377T1 (el) 2016-06-22
WO2010056588A1 (en) 2010-05-20
EP2358698A1 (en) 2011-08-24
BRPI0921782A2 (pt) 2019-09-24
SI2358698T1 (sl) 2012-11-30
EA201170699A1 (ru) 2011-12-30
JP2012509263A (ja) 2012-04-19
CA2743483C (en) 2014-03-11
EA017386B1 (ru) 2012-12-28
CN102216285A (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
SMT201400123B (it) Imidazo[1,2B]piridazine sostituite come inibitori di trk-chinasi
DK2364293T3 (da) Hidtil ukendte pyrazol-4-N-alkoxycarboxamider som mikrobiocider
DK2280962T3 (da) Pyridazinderivater
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
BRPI0908116A2 (pt) pulverizador
NO2021006I1 (no) Quofenix, delafloksacin
ME02397B (me) Pirazolo[1,5-a]pirimidini i -triazini kao antiviralni agensi
DK2401256T3 (da) Forbindelser som bradykinin-B1-antagonister.
BRPI0907165A2 (pt) R-2-(4-ciclopropanossulfonil-fenil)-n-pirazin-2-il-3-(t etra-hidropiran-4-il)-propionamida cristalina
ATE527260T1 (de) (dihydro)pyrroloä2,1-aüisoquinoline
DK2373644T3 (da) Pyridazinonderivater
DK2342182T3 (da) Isoquinolinonderivater som nk3-antagonister
BRPI0918173A2 (pt) estrutura em degraus
IT1396642B1 (it) Statore.
UA18855S (uk) Гіпертермотерапевтичне крісло
DK2373647T3 (da) Pyridazinonderivater
UA19972S (uk) Сидіння
ITME20080002A1 (it) Filcomplex - potabilizzatore di acque.
UA17812S (uk) Табурет
UA17654S (uk) Стілець
UA17980S (uk) Стілець
TH99857B (th) เก้าอี้
UA18858S (uk) Крісло
UA17813S (uk) Крісло
TH100453B (th) เก้าอี้